vTv Therapeutics (VTVT) EBITDA Margin (2014 - 2026)

vTv Therapeutics (VTVT) posted EBITDA Margin of 63.15% for Q1 2026, up 100.22% sequentially from 28776.47% in Q4 2024.

vTv Therapeutics (VTVT) EBITDA Margin (2014 - 2026) Analysis & Trends

vTv Therapeutics has reported EBITDA Margin for 11 years, with the latest figure at 63.15% in Q1 2026.

Quarterly EBITDA Margin changed N/A year-over-year to 63.15% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 8.26% (up 14737998.0% YoY) and the FY2024 annual result came in at 2377.58%, changed N/A from the prior year.
EBITDA Margin rose to 63.15% in Q1 2026 per VTVT's latest filing, from 28776.47% in the prior quarter.
Over five years, EBITDA Margin peaked at 63.15% in Q1 2026 and troughed at 70477.78% in Q4 2022.
A 3-year average of 24137.05% and a median of 14669.59% in 2024 frame the typical range for EBITDA Margin.
The widest YoY moves for EBITDA Margin: up 5295556 bps in 2022, down 10959 bps in 2022.
Over 3 years, EBITDA Margin stood at 70477.78% in 2022, then surged by 59 bps to 28776.47% in 2024, then surged by 100 bps to 63.15% in 2026.
According to Business Quant data, EBITDA Margin over the past three periods registered 63.15%, 28776.47%, and 562.7% for Q1 2026, Q4 2024, and Q1 2024 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBITDA Margin (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	37.40%
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	30.15%
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	31.68%
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	19.06%
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	-77,569,866.34%
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	19.75%
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	17.93%
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	-0.36%
10	vTv Therapeutics	373.77 Mn	373.77 Mn	-	-

Download Data